PI3Kδ Inhibitor Dosing Regimen for Lower Toxicity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors, particularly those targeting the δ isoform, are associated with serious adverse effects such as hepatotoxicity, diarrhoea/colitis, respiratory infections, and hematological toxicities, limiting their use and efficacy in treating diseases like cancer and autoimmune disorders.
Innovation Solution
A compound, specifically a PI3Kδ inhibitor in the form of a hemifumarate salt, is administered in controlled doses ranging from 18 mg to 108 mg per day, offering a favourable safety profile by minimizing treatment-related ALT elevation, diarrhoea, colitis, and neutropenia, and is formulated for oral administration in tablets or capsules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PI3Kδ inhibitors are used to treat cancer and autoimmune diseases, then the therapeutic efficacy is improved, but serious adverse effects such as hepatotoxicity, diarrhoea/colitis, respiratory infections, and haematological toxicities occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of PI3Kδ inhibitors to achieve isoform-selectivity. The compound of formula (I) features specific structural modifications including a heterocyclic ring system with particular substituent patterns that confer selectivity for PI3Kδ over other PI3K isoforms. This structural parameter change reduces off-target effects while maintaining therapeutic efficacy against PI3Kδ-driven diseases.
Solution Approach 2:
The patent implements local quality by designing the inhibitor molecule with specific functional groups positioned at particular locations on the molecular scaffold. The heterocyclic core structure with specific substituents at defined positions creates localized interaction patterns that selectively bind to the PI3Kδ ATP-binding pocket, distinguishing it from other PI3K isoforms and reducing class-wide toxicity.
2Reliability
If PI3Kδ inhibitors are administered at higher doses to improve efficacy, then the therapeutic benefit increases, but the incidence and severity of adverse effects increase
Solution Approach 1:
The patent employs parameter changes by optimizing the molecular parameters of the inhibitor to achieve high target affinity and selectivity at lower concentrations. The compound of formula (I) exhibits potent inhibition of PI3Kδ with selectivity over other isoforms, allowing effective doses that minimize off-target effects and class-related toxicities.
3Duration of action of moving object
If treatment duration is extended to improve patient outcomes, then the therapeutic benefit increases, but the accumulation of adverse effects and safety concerns increase
Solution Approach 1:
The patent applies parameter changes by developing a compound with an optimized safety profile that enables prolonged treatment. The selective PI3Kδ inhibition by the compound of formula (I) maintains therapeutic efficacy while reducing the accumulation of adverse effects over time, allowing extended treatment durations for chronic conditions.
Data Source
AI summary
A compound or a pharmaceutically acceptable salt thereof for use in a method of treatment of a disease or condition in which signalling through the PI3Kδ pathway is pathologically implicated in patients, for example cancer and inflammatory or autoimmune diseases. The compound is provided at a specified dose and has been found to have a favourable safety profile in humans, in particular with regard to hepatotoxicity, diarrhoea/colitis, respiratory infections, and hematologic toxicities.